Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats

Autores
Albarellos, Gabriela A.; Montoya, Laura; Denamiel, Graciela A.A.; Passini, Sabrina M.; Landoni, María Fabiana
Año de publicación
2013
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
Facultad de Ciencias Veterinarias
Materia
Ciencias Veterinarias
Antimicrobials
Lincosamides
Pharmacokinetics
Skin concentrations
cats
Nivel de accesibilidad
acceso abierto
Condiciones de uso
http://creativecommons.org/licenses/by/4.0/
Repositorio
SEDICI (UNLP)
Institución
Universidad Nacional de La Plata
OAI Identificador
oai:sedici.unlp.edu.ar:10915/85369

id SEDICI_5cf271a58cc6e66044d6c45ef2a5a255
oai_identifier_str oai:sedici.unlp.edu.ar:10915/85369
network_acronym_str SEDICI
repository_id_str 1329
network_name_str SEDICI (UNLP)
spelling Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to catsAlbarellos, Gabriela A.Montoya, LauraDenamiel, Graciela A.A.Passini, Sabrina M.Landoni, María FabianaCiencias VeterinariasAntimicrobialsLincosamidesPharmacokineticsSkin concentrationscatsThe aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.Facultad de Ciencias Veterinarias2013info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArticulohttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfhttp://sedici.unlp.edu.ar/handle/10915/85369enginfo:eu-repo/semantics/altIdentifier/issn/1019-9128info:eu-repo/semantics/altIdentifier/doi/10.4102/jsava.v84i1.968info:eu-repo/semantics/openAccesshttp://creativecommons.org/licenses/by/4.0/Creative Commons Attribution 4.0 International (CC BY 4.0)reponame:SEDICI (UNLP)instname:Universidad Nacional de La Platainstacron:UNLP2025-09-03T10:48:51Zoai:sedici.unlp.edu.ar:10915/85369Institucionalhttp://sedici.unlp.edu.ar/Universidad públicaNo correspondehttp://sedici.unlp.edu.ar/oai/snrdalira@sedici.unlp.edu.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:13292025-09-03 10:48:51.946SEDICI (UNLP) - Universidad Nacional de La Platafalse
dc.title.none.fl_str_mv Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
spellingShingle Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
Albarellos, Gabriela A.
Ciencias Veterinarias
Antimicrobials
Lincosamides
Pharmacokinetics
Skin concentrations
cats
title_short Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_full Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_fullStr Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_full_unstemmed Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
title_sort Pharmacokinetics and skin concentrations of lincomycin after intravenous and oral administration to cats
dc.creator.none.fl_str_mv Albarellos, Gabriela A.
Montoya, Laura
Denamiel, Graciela A.A.
Passini, Sabrina M.
Landoni, María Fabiana
author Albarellos, Gabriela A.
author_facet Albarellos, Gabriela A.
Montoya, Laura
Denamiel, Graciela A.A.
Passini, Sabrina M.
Landoni, María Fabiana
author_role author
author2 Montoya, Laura
Denamiel, Graciela A.A.
Passini, Sabrina M.
Landoni, María Fabiana
author2_role author
author
author
author
dc.subject.none.fl_str_mv Ciencias Veterinarias
Antimicrobials
Lincosamides
Pharmacokinetics
Skin concentrations
cats
topic Ciencias Veterinarias
Antimicrobials
Lincosamides
Pharmacokinetics
Skin concentrations
cats
dc.description.none.fl_txt_mv The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
Facultad de Ciencias Veterinarias
description The aim of the present study was to describe the plasma pharmacokinetic profile and skin concentrations of lincomycin after intravenous administration of a 15% solution and oral administration of 300 mg tablets at a dosing rate of 15 mg/kg to cats. Susceptibility of staphylococci (n = 31) and streptococci (n = 23) strains isolated from clinical cases was also determined. Lincomycin plasma and skin concentrations were determined by microbiological assay using Kocuria rhizophila ATCC 9341 as test microorganism. Susceptibility was established by the antimicrobial disc diffusion test. Individual lincomycin plasma concentration-time curves were analysed by a non-compartmental approach. After intravenous administration, volume of distribution, body clearance and elimination half-life were 0.97 L/kg ± 0.15 L/kg, 0.17 L/kg ± 0.06 L/h.kg and 4.20 h ± 1.12 h, respectively. After oral administration, peak plasma concentration, time of maximum plasma concentration and bioavailability were 22.52 μg/mL ± 10.97 μg/mL, 0.80 h ± 0.11 h and 81.78% ± 24.05%, respectively. Two hours after lincomycin administration, skin concentrations were 17.26 μg/mL ± 1.32 μg/mL (intravenous) and 16.58 μg/mL ± 0.90 μg/mL (oral). The corresponding skin: plasma ratios were 2.08 ± 0.47 (intravenous) and 1.84 ± 0.97 (oral). The majority of staphylococci and streptococci tested in this study were susceptible to lincosamides (87.09% and 69.56%, respectively). In conclusion, lincomycin administered orally at the assayed dose showed a good pharmacokinetic profile, with a long elimination half-life and effective skin concentration. Therefore, it could be a good first option for treating skin infections in cats.
publishDate 2013
dc.date.none.fl_str_mv 2013
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Articulo
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://sedici.unlp.edu.ar/handle/10915/85369
url http://sedici.unlp.edu.ar/handle/10915/85369
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/issn/1019-9128
info:eu-repo/semantics/altIdentifier/doi/10.4102/jsava.v84i1.968
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
eu_rights_str_mv openAccess
rights_invalid_str_mv http://creativecommons.org/licenses/by/4.0/
Creative Commons Attribution 4.0 International (CC BY 4.0)
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:SEDICI (UNLP)
instname:Universidad Nacional de La Plata
instacron:UNLP
reponame_str SEDICI (UNLP)
collection SEDICI (UNLP)
instname_str Universidad Nacional de La Plata
instacron_str UNLP
institution UNLP
repository.name.fl_str_mv SEDICI (UNLP) - Universidad Nacional de La Plata
repository.mail.fl_str_mv alira@sedici.unlp.edu.ar
_version_ 1842260364715098112
score 13.13397